✦ LIBER ✦

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

✍ Scribed by Sumitra THONGPRASERT; Sirana TINMANEE; Unchalee PERMSUWAN

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN34 COST-EFFECTIVENESS OF GEFITINIB FO

✍ PH Liu; FC Hu; JD Wang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

OP3 Cost-effectiveness of epidermal grow

✍ G. de Lima Lopes; J. Segel; D. Tan; Y. Do; T. Mok; E. Finkelstein 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB

Egfr Test-Guided Erlotinib Versus Chemot

✍ Bajaj, P.S.; Carlson, J.J.; Goertz, H.P.; Veenstra, D.L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN32 COST-MINIMISATION ANALYSIS OF ERLO

✍ S Stefani; MG Saggia; EA Santos 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

A comparison of individualized treatment

✍ Nelson, Richard E.; Stenehjem, David; Akerley, Wallace 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 815 KB